NSCLC: Nivolumab Extends 5-Year Survival in Heavily Pretreated Patients

(MedPage Today) -- In phase I study, no evidence of progression or need for subsequent therapy in 12 of 16 patients
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news